Bifidobacterium Bifidum
Bifidobacterium bifidum
TL;DR
B. bifidum is a native human gut species with one genuinely strong single-strain result: MIMBb75 improved global IBS symptoms in placebo-controlled trials. Outside IBS, most evidence comes from multi-strain blends where its individual contribution is unclear.
Ideal For
- Adults with IBS wanting a single-strain option with placebo-controlled data
- People rebuilding gut flora after antibiotics as part of a blend
Avoid If
- You are severely immunocompromised or critically ill
- You have a central venous catheter
- You are buying a product with no strain designation and expect trial-level results
- You need same-week relief - allow 4-8 weeks
Frequently Asked Questions
What does Bifidobacterium bifidum do?
What has it been studied for?
What dose is typical?
Should it be taken with antibiotics?
Does it need refrigeration?
Who should be cautious?
Overview
Bifidobacterium bifidum is one of the first colonisers of the infant gut and remains a resident species in adults, where it specialises in degrading host mucin glycans and shares the resulting sugars with neighbouring bacteria - a cross-feeding role that underpins its reputation as a community builder. Clinically, the standout is strain MIMBb75: in a German placebo-controlled trial, eight weeks of this single strain improved global IBS symptoms, pain and quality of life significantly more than placebo, and a later trial using a heat-inactivated version reproduced the benefit, which is unusual and suggests surface-protein adhesion rather than colonisation drives the effect. Beyond IBS, B. bifidum appears in multi-strain formulas studied for antibiotic-associated diarrhoea, ulcerative colitis maintenance and immune endpoints in older adults, where separating its contribution from the other strains is impossible. Strain specificity is the practical takeaway: buying "B. bifidum" without a strain designation buys the species name, not the trial data.
How It Works
- Degrades host mucin glycans and cross-feeds short-chain-fatty-acid producers
- Surface proteins adhere to intestinal epithelium and modulate visceral hypersensitivity
- Strengthens tight-junction integrity in epithelial models
- Modulates dendritic cell and regulatory T-cell responses in gut-associated lymphoid tissue
Benefits & Outcomes
No linked outcomes yet. Research is ongoing.
Supporting Research12 studies
The Effect of Probiotic Yogurt Containing Lactobacillus rhamnosus and Bifidobacterium bifidum on Disease Activity and Disability in Patients with Systemic Lupus Erythematosus: A Randomized Controlled Trial
Banaki R, Faezi ST, Esmaeilzadeh A +3 more
did not have a significant short-term effect on SLEDAI and disability in SLE patients
Changes in Gut Microbiota and Systemic Inflammation after Synbiotic Supplementation in Patients with Systemic Lupus Erythematosus: A Randomized, Double-Blind, Placebo-Controlled Trial
Widhani A, Djauzi S, Suyatna FD +1 more
Synbiotic supplementation could reduce systemic inflammation and SLE disease activity
Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial
Andresen V, Gschossmann J, Layer P
Heat-inactivated B. bifidum MIMBb75 achieved the composite responder endpoint in 34% of patients versus 19% on placebo over 8 weeks.
Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life - a double-blind, placebo-controlled study
Guglielmetti S, Mora D, Gschwender M +1 more
B. bifidum MIMBb75 reduced global IBS symptoms in 57% of patients versus 21% on placebo, with significant improvements in pain, distension and quality of life over 4 weeks.
Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study
Langkamp-Henken B, Rowe CC, Ford AL +2 more
B. bifidum resulted in a greater proportion of healthy days than placebo (P<=0.05).
Add-On Bifidobacterium bifidum Supplement in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Week Randomized Double-Blind Placebo-Controlled Clinical Trial
Wang LJ, Tsai CS, Chou WJ +2 more
The group receiving Bf-688 supplementation, but not the placebo group, exhibited significant improvements in omission errors in CPT as well as Hit reaction time in both CPT and CATA.
A randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of the gut microbiota and relief from chronic constipation
Wang L, Wang L, Tian P +2 more
B. bifidum CCFM16 treatment improved the stool consistency and increased the proportion of SBM responders, but the differences in PAC-SYM and PAC-QoL were statistically insignificant between the groups.
Bifidobacterium and enteral feeding in preterm infants: cluster-randomized trial
Totsu S, Yamasaki C, Terahara M +2 more
Enteral feeding was established significantly earlier in the B group, at 11.0 +/- 3.6 days versus 12.1 +/- 3.8 days in P group (P < 0.05).
Probiotic Supplementation Improves Cognitive Function and Mood with Changes in Gut Microbiota in Community-Dwelling Older Adults
Relative abundance of inflammation-causing gut bacteria was significantly reduced at Week 12 in the probiotics group (p < .05).
Comparative effectiveness of probiotic strains for the treatment of pediatric atopic dermatitis: A systematic review and network meta-analysis
Tan-Lim CSC, Esteban-Ipac NAR, Mantaring JBV +2 more
Mix6 compared with placebo probably reduces atopic dermatitis symptoms based on moderate certainty evidence (SMD -0.85, 95% CI -1.50 to -0.20; 40 participants).
Effect of Supplementation with a Specific Probiotic (Bifidobacterium bifidum PRL2010) in Pregnancy for the Prevention of Atopic Dermatitis in Children
Anania C, Matys V, Marra S +2 more
Although proportionally fewer children with AD were in the probiotic group, the statistical analysis showed no significant differences between the probiotic and placebo groups.
Efficacy of a Probiotic Consisting of Lacticaseibacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911, and Bifidobacterium longum subsp. longum PDV 2301 in the Treatment of Hospitalized Patients with COVID-19: a Randomized Controlled Trial
Ivashkin V, Fomin V, Moiseev S +2 more
No significant differences in mortality, total duration of disease were found between the groups.
Safety Information
Potential Side Effects
Transient gas or bloating in the first week. Generally very well tolerated.
Contraindications
Severe immunosuppression, central venous catheters, or critical illness (rare bacteraemia risk).
Drug Interactions
- Antibiotics (separate doses by 2-3 hours)
- Immunosuppressants (theoretical infection risk)
Pregnancy & Breastfeeding
Pregnancy: Likely safe
Breastfeeding: Likely safe
Dosage Guidelines
Dosage Used in Studies
1-10 billion CFU
Best Time to Take
Once daily, consistently
Best Form
Strain-designated capsule (MIMBb75 for IBS)
Forms Compared
Single-strain capsule
MIMBb75 is the IBS-studied strain, roughly 1 billion CFU/day
Heat-inactivated (postbiotic)
Reproduced the IBS benefit and is shelf-stable
Multi-strain blend
Common; the individual contribution of B. bifidum is untested
Food & Timing
With or shortly before a meal to buffer stomach acid.
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.